Evidence map›Paper›PMID 33102632›Full record

ArticleEuropean journal of radiology open2020

Tumor volume dynamics and tumor growth rate in

Mizuki Nishino, Tomoyuki Hida, Sasha Kravets, Suzanne E Dahlberg, Christine A Lydon, Hiroto Hatabu, Bruce E Johnson, Mark M Awad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of radiology open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mizuki NishinoDepartment of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Tomoyuki HidaDepartment of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Sasha KravetsDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Suzanne E DahlbergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Christine A LydonDepartment of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA, 02215, USA.
Hiroto HatabuDepartment of Radiology, Brigham and Women's Hospital and Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Bruce E JohnsonDepartment of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA, 02215, USA.
Mark M AwadDepartment of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA, 02215, USA.
Dana-Farber Cancer Institute · USDana-Farber Brigham Cancer Center · USBrigham and Women's Hospital · US

Funding

Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9M
NCI NIH HHS R01 CA203636
6 · The paper itself

Abstract

purposeThe purpose of the study is to investigate volumetric tumor burden dynamics and tumor growth rates in

methodsThe study included 44

resultsA total of 231 volume measurements from the nadir to the end of crizotinib therapy or the last follow-up in 44 patients were analyzed in a linear mixed-effects model, fitting time (in months since baseline) as a random effect. When measured from the volume nadir, the tumor growth rate of the logarithm of tumor volume (log

conclusionsTumor volume growth rate after nadir in

Indexed as

ALK rearrangementCrizotinibLung cancerNon-small cellPrecision therapyTumor growth rate

Identifiers

PMID33102632
PMCPMC7569410
OpenAlexW3003595552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.